OpenEvidence vs UpToDate: Which Is Better in 2026?

Most clinicians did not choose their clinical reference. It came with the hospital, or with residency, and it has been there ever since. UpToDate has held that position for two decades.

OpenEvidence arrived differently. It is free to verified US clinicians, it answers questions rather than serving topic pages, and it has signed content agreements with NEJM, JAMA, Nature, NCCN and Cochrane. For a lot of physicians it became a daily habit before anyone made a procurement decision about it.

So the question is no longer which one is better in the abstract. It is which one you should reach for at the point of care, and whether you need both. This comparison covers what each one actually is, where each genuinely wins, what they cost, and what neither of them does.

TL;DR

OpenEvidence is the better choice if your questions are specific, you practise in the US, and you want licensed primary literature answered conversationally at no cost. UpToDate is the better choice if you need graded, attributable recommendations, CME, or you practise outside the US. A large number of clinicians reasonably use both, and the rest of this post is about when each one earns the click.

OpenEvidence vs UpToDate: Quick Comparison

Who Is OpenEvidence Best For?

A US-based clinician who thinks in questions rather than topics. If your instinct at the bedside is "does the evidence support anticoagulating this particular patient" rather than "let me read about atrial fibrillation", OpenEvidence is built for that shape of query, and it answers from literature it has licensed rather than summarised second-hand.

It suits people who are cost-sensitive, including residents, fellows and anyone whose institution does not provide a reference subscription. It is free to verified clinicians in the US and, since September 2026, Canada, which removes the decision rather than winning it.

It also suits oncologists and anyone working close to guideline-driven care, because the NCCN collaboration puts treatment algorithms inside the product and the Memorial Sloan Kettering and OneOncology partnerships point the same direction.

Who Is UpToDate Best For?

A clinician who needs to stand behind a recommendation, not just find one. UpToDate's topic reviews carry named authors, named editors and a grading system, which matters when the question is not only "what does the evidence say" but "what will a reviewer, a colleague or a court make of why I did this".

It also suits anyone practising in the UK or Europe, where OpenEvidence is not currently available, and the very large group of clinicians whose hospital, university or residency programme already pays for it. Wolters Kluwer puts UpToDate's reach at over 3 million health professionals worldwide, and that ubiquity is itself a feature: your colleagues are reading the same topic review you are.

How We Tested OpenEvidence and UpToDate

This comparison covers answer format and scope, evidence sourcing and citation, recommendation grading and attribution, specialty coverage, workflow at the point of care, and access and cost.

We did not hold a paid UpToDate subscription or a verified OpenEvidence clinician account for this comparison. Every claim here is listed: taken from each vendor's own published documentation, or from a named third-party source, with the source and the date it was read given alongside it. Features marked "coming soon" are noted and not treated as available.

Where the two vendors describe the same capability differently, we have used their own wording rather than normalising it, because the difference in framing is often the substance of the difference.

How Does Answer Scope Compare?

The two tools answer different shapes of question, and this is the single most useful thing to understand about them.

OpenEvidence takes a clinical question and returns a synthesised answer. It describes itself as an AI copilot for doctors making high-stakes decisions at the point of care, and reports over 200 million clinical consultations from US clinicians to date (openevidence.com/about, read October 2026). The unit of use is the question.

UpToDate takes a topic and returns a review of it. The unit of use is the subject, and the review is written to be read, not queried. That is slower when your question is narrow, and considerably better when your question is broad or when you do not yet know what you are looking for.

Neither approach is superior in general. They are suited to different moments in clinical work, which is why clinicians who have access to both tend to use both.

The scale behind each is worth knowing, because it shapes what you get. Wolters Kluwer describes UpToDate as trusted by over 3 million health professionals worldwide, assembled by more than 7,600 expert clinicians, editors and reviewers (wolterskluwer.com, read October 2026). That is a publishing operation. OpenEvidence reports over 200 million AI-powered clinical consultations from US clinicians to date, and in September 2026 announced its own OpenEvidence Model Family. That is a software operation. Both numbers are vendor-reported, and both describe something real about what the product is underneath.

How Does Evidence and Citation Compare?

This is where OpenEvidence's position is strongest and most concrete.

OpenEvidence states official AI partnerships with The New England Journal of Medicine, JAMA and the JAMA Network specialty journals, Nature and the Nature Portfolio, and Cochrane Systematic Reviews, plus an official AI collaboration with the NCCN covering NCCN Guidelines Treatment Algorithms. Its own documentation says its content includes figures, tables, multimedia and full-text clinical findings from those sources (openevidence.com/about, read October 2026). That is licensed primary literature, not a third-party summary of it.

UpToDate's model is different in kind. Its content is commissioned and written by named clinical authors, then edited and peer reviewed. The evidence behind a statement is cited, but what you are reading is an expert's synthesis rather than the literature itself.

OpenEvidence has continued to add to that licensed base: an agreement with Springer Nature in August 2026 and a partnership with Sage in September 2026, both framed around bringing peer-reviewed research to the point of care.

UpToDate's counterweight is editorial scale and outcome evidence. Wolters Kluwer cites over 100 research studies finding that UpToDate improves health outcomes, and the 7,600-person editorial network is the mechanism: content is commissioned, reviewed and maintained rather than retrieved.

The practical difference: OpenEvidence gets you closer to the source document, and UpToDate gets you closer to an expert's judgement about what the source document means. Which of those you want depends on whether you are checking a fact or forming a plan.

How Does Reasoning Transparency Compare?

Both tools show you where an answer came from. Neither shows you how it got there.

OpenEvidence cites the literature behind its answers. What it does not do, by its own description, is expose a stepwise account of how it moved from your question to its conclusion. You can check the sources; you cannot audit the reasoning.

UpToDate's position changed in 2026. Wolters Kluwer now ships UpToDate Expert AI, a generative layer over the same expert-authored content, and markets "Transparent reasoning" as one of its named features alongside inline citations, a Sources section and surfaced assumptions about the question you asked (listed, wolterskluwer.com, read November 2026). Underneath it, the editorial model is unchanged: a human author's synthesis with a grade attached.

How much of a chain of reasoning either tool actually exposes is harder to settle than it looks. OpenEvidence shows the literature behind an answer. UpToDate advertises transparent reasoning with assumptions surfaced. We did not hold a paid seat on either product for this comparison, so we cannot tell you how much of the inference is genuinely inspectable in practice as opposed to well cited. Treat both claims as the vendors' own.

How Does Specialty Depth Compare?

UpToDate's depth is a function of editorial investment: topics that have been written, reviewed and maintained by specialists over years. Coverage is broad and the depth is uneven in the way any commissioned library is uneven, but in well-covered areas it is very deep.

OpenEvidence's depth is a function of what it has licensed. With NEJM, JAMA, Nature, Cochrane and NCCN content under agreement, its coverage follows those bodies of literature, which is strong in oncology, internal medicine and the areas those journals cover most heavily.

OpenEvidence has been building specialty depth through institutional collaboration rather than commissioning: partnerships announced during 2026 include Memorial Sloan Kettering on precision oncology, Johns Hopkins Medicine, Penn Medicine, Boston Children's Hospital, OneOncology, and the American Medical Society for Sports Medicine. Those are relationships with specialty institutions rather than specialty-specific product configurations, but they shape where the content is strongest.

Neither is organised around subspecialty-scoped reasoning. You are querying a general system that reaches into specialty literature, rather than consulting something configured for your subspecialty specifically. For a generalist that distinction rarely matters. For a subspecialist asking a question inside their own field, it is often the whole difference between a useful answer and a familiar one.

How Does Workflow and Speed Compare?

OpenEvidence is faster for a narrow question, because the question is the interface. There is no navigation step between asking and answering.

UpToDate is faster when you need orientation rather than an answer. If you do not yet know the right question, a topic review gets you there more reliably than a query will.

Where they differ more sharply is how far into your workflow they reach. UpToDate states availability inside the EHR, including content sets through Epic, on mobile, and in remote locations. That is a mature integration story built over years of enterprise deployment. OpenEvidence has been assembling something comparable through health-system collaborations: Northwestern Medicine announced an integration of clinical evidence into the EHR in October 2026, and UTMB announced integration into clinical workflows in September 2026.

The difference is maturity rather than intent. UpToDate's integration is a product you can buy; OpenEvidence's is, at the time of writing, a set of named institutional collaborations. If EHR integration is a procurement requirement, that distinction matters.

For bedside use, both are usable on mobile, and both are quick enough that speed is rarely the deciding factor. The deciding factor is almost always whether you arrived with a question or with a subject.

How Does Access and Deployment Compare?

OpenEvidence is free to verified US clinicians, and verification is the gate. Its access model is individual rather than institutional, which means you do not need anyone's approval to start using it and your institution does not need to buy anything.

That model has a geographic limit. According to a September 2026 analyst review of the clinical AI market, OpenEvidence withdrew from the UK and EU in April 2026, leaving clinicians in those markets without access. If you practise outside the US, this is likely the deciding fact in the comparison.

That geographic limit is narrower than it was. In September 2026 OpenEvidence announced a partnership to provide free access for Canadian physicians, so the product is not US-only. But clinicians in the UK and Europe remain without access, and for them the comparison ends here.

UpToDate is sold primarily through institutions, with individual subscriptions available, and is available internationally. For most clinicians the practical access question is not what it costs but whether their employer already provides it, and very often the answer is yes.

Where Does OpenEvidence Genuinely Win?

1. Licensed primary literature

The content agreements with NEJM, JAMA, Nature, Cochrane and NCCN are not marketing framing. They mean full-text findings from those sources are inside the product under licence. No competitor in this category has an equivalent set of partnerships.

2. Cost

Free to verified US clinicians, with no institutional procurement. For a resident, a fellow, or a physician whose employer provides nothing, this removes the decision entirely rather than winning it on price.

3. The question is the interface

For narrow, specific, patient-shaped questions, asking is faster than navigating, and OpenEvidence is built around asking.

4. Adoption and institutional momentum

Its own documentation describes it as the most widely used medical AI among verified US clinicians, with over 200 million clinical consultations to date. Through 2026 it announced collaborations with Memorial Sloan Kettering, Johns Hopkins Medicine, Penn Medicine, Northwestern Medicine, Boston Children's Hospital and AdventHealth, among others. Whatever weight you give a vendor's own numbers, that list is not something a marketing team can manufacture.

5. It is closing the gaps that used to define the comparison

A year ago the easy summary was that OpenEvidence was free but lacked credit, integration and reach. In 2026 it launched CE and MOC credit, added Canadian access, signed Springer Nature and Sage, and began EHR integrations with named health systems. Any comparison of these two tools dates quickly, which is the honest caveat on everything above.

Where Does UpToDate Genuinely Win?

1. Attributable, graded recommendations

A named author, a named editor, peer review and a grade. When you need to explain why you did something, to a colleague, a committee or a reviewer, that chain is worth more than a correct answer with no provenance.

2. Breadth of accredited credit

This was a clean UpToDate win until recently and is now a narrower one. OpenEvidence launched an education platform offering Continuing Education and Maintenance of Certification credit in July 2026. UpToDate's advantage is no longer that it offers credit and the alternative does not; it is that its CME/CE/CPD is accepted by dozens of accrediting organisations and specialty boards internationally, and has been for years. If your board is unusual, or you practise across jurisdictions, that established acceptance is still worth something. Check your own board against both before assuming either.

3. Availability where OpenEvidence is not

UpToDate is available internationally. OpenEvidence covers the US and, since September 2026, Canada, but withdrew from the UK and EU. For clinicians in those markets this is not a marginal advantage, it is the entire comparison, and no amount of capability on the other side changes it.

4. No advertising in the answers

UpToDate is funded by subscriptions. OpenEvidence is advertising-supported, and the advertisers in this category are pharmaceutical companies. Reasonable clinicians differ on how much this matters, but it is a real structural difference in who pays for the answer you are reading, and it is worth knowing which model you are using.

5. Mature EHR and workflow integration

UpToDate is available inside the EHR, including content sets through Epic, on mobile and in remote locations. OpenEvidence is building equivalent reach through named health-system collaborations, but as a procurement item UpToDate's integration is finished and purchasable today.

6. You probably already have it

Institutional access is the quiet reason UpToDate stays in workflows. If your hospital pays for it, the marginal cost of continuing is zero, and no comparison of list prices changes that arithmetic.

What Neither Tool Covers

Both tools answer clinical questions well, in different ways. Neither currently offers:

• A reasoning trace you can audit rather than read about. Both vendors now describe transparency: OpenEvidence cites the literature, UpToDate Expert AI advertises transparent reasoning with assumptions surfaced. Neither publishes an account of how an answer was reached that a reader could independently check.

• Subspecialty-scoped reasoning. Both are general systems reaching into specialty literature. Neither is configured so that a question is answered at the depth a colleague in that subspecialty would bring.

• An ad-free AI layer. UpToDate has no advertising. OpenEvidence is advertising-supported. A clinician who wants an AI-native tool with no advertising in the output has to look past the free option.

• Access outside the United States for an AI-native tool. OpenEvidence has withdrawn from the UK and EU. UpToDate Expert AI is available in select markets only, and is a reference-only tool rather than a clinical decision support tool in some jurisdictions (listed, wolterskluwer.com, read November 2026).

For clinicians who want an AI tool that reasons at subspecialty depth, shows its working, and carries no pharmaceutical advertising in the output, platforms like AtlasGPT are built around that combination, covering 41 subspecialties with inline citations and a visible reasoning trace. AtlasGPT's own neurosurgery evaluation is published in the Journal of Neurosurgery.

Pricing Comparison

Two things about this table matter more than the numbers.

First, UpToDate does not publish its individual pricing on a readable page; its store gates pricing behind a country and role selector. The figures above come from a named third-party roundup and are dated accordingly. Treat them as approximate.

Second, and more importantly for most readers: you may already have UpToDate. A very large share of clinicians access it through a hospital, university or residency programme at no personal cost. If that is you, the list price is not the relevant number and the comparison is not really about money. It is about whether a free AI-native tool earns a place alongside a reference you already have.

Final Verdict: Should You Choose OpenEvidence or UpToDate?

Choose OpenEvidence if:

• You practise in the United States or Canada and can verify as a clinician.

• Your questions are specific and patient-shaped rather than topic-shaped.

• You want licensed full-text findings from NEJM, JAMA, Nature, Cochrane and NCCN.

• You have no institutional subscription and no budget for one.

• You are comfortable with an advertising-supported model.

Choose UpToDate if:

• You need graded recommendations with named authorship behind them.

• You practise in the UK, Europe, or outside OpenEvidence's current markets.

• You need CME credit from your point-of-care lookups.

• You want no advertising in the content you rely on.

• Your institution already provides it.

The honest answer for many US clinicians is both: OpenEvidence for the fast specific question, UpToDate when the recommendation has to be defensible. Neither choice is a mistake.

Where AtlasGPT Fits

AtlasGPT has been through something neither tool above has: peer review of its own model, with the results open to inspection. It is built by Atlas Meditech and founded by neurosurgeon Dr. Aaron Cohen-Gadol, recipient of the Vilhelm Magnus Medal and founder of The Neurosurgical Atlas, and it covers 41 subspecialties.

It is built around the three gaps listed earlier:

• Reasoning you can read, at subspecialty depth. Not a citation list and not a summary: the steps between the question and the conclusion, answered inside the subspecialty rather than by a general system reaching into specialty literature.

• Subspecialty-scoped reasoning across 41 subspecialties, rather than a general system reaching into specialty literature.

• No pharmaceutical advertising in the output. Clinician-validated by 1,000+ attending physicians, and HIPAA-ready infrastructure is available on Enterprise.

The published evaluation is where this stops being a claim. Ali R, et al., Journal of Neurosurgery 2025;143:560-567 put the model through a 149-question neurosurgery examination and had 15 independent neurosurgeons rate its answer explanations:

• 96% accuracy, against Gemini Advanced at 93% and GPT-4 at 88%.

• Fooled by deliberately planted medical misinformation 14% of the time, against GPT-4 at 44% and Gemini Advanced at 68%.

• Explanations rated more comprehensive, more relevant and better referenced than the question bank's own, p < 0.001.

Where it earns a place is the case that is genuinely hard, where you want to read the reasoning rather than spot-check the citations. Bring one real case to AtlasGPT and check its working against your own. See pricing or the full comparison with UpToDate.

Frequently Asked Questions

Is OpenEvidence free?

Yes, for verified US clinicians. Verification of clinician status is the gate rather than payment. The platform is advertising-supported, which is how a free product in this category is funded.

Is OpenEvidence better than UpToDate?

Neither is better in general. OpenEvidence is better for specific questions answered from licensed primary literature at no cost. UpToDate is better for graded, attributable recommendations, CME credit, and access outside the US.

Can I use OpenEvidence and UpToDate together?

Yes, and many clinicians do. They answer different shapes of question. Using OpenEvidence for narrow queries and UpToDate when a recommendation needs to be defensible is a common and sensible pattern.

Does OpenEvidence have NEJM content?

Yes. OpenEvidence states it is an Official AI Partner of The New England Journal of Medicine and that its content includes figures, tables, multimedia and full-text clinical findings from NEJM, alongside similar agreements with JAMA, Nature, Cochrane and NCCN.

Is OpenEvidence available outside the United States?

Partly. It announced free access for Canadian physicians in September 2026. It is not available in the UK or EU, having withdrawn from those markets in April 2026 according to a September 2026 analyst review. Clinicians outside the US and Canada should confirm current availability directly with the vendor.

How much does UpToDate cost?

UpToDate does not publish individual pricing on a readable page; its store gates pricing behind a country and role selector. Third-party roundups give roughly $579 per year for standard access and about $699 for Pro Plus, which includes Expert AI, as of July 2026. Many clinicians access it free through an institution.

Does OpenEvidence offer CME credit?

Yes, as of July 2026, when it launched an education platform offering Continuing Education and Maintenance of Certification credit. This used to be a clear point of difference and is no longer. UpToDate's CME/CE/CPD has longer-established acceptance across dozens of accrediting organisations, so check your own board against both.

Does either tool show its reasoning?

Both now say they do, in different ways. OpenEvidence cites the sources behind an answer. UpToDate Expert AI lists "Transparent reasoning" as a feature, with inline citations and surfaced assumptions (listed, wolterskluwer.com, read November 2026). We held no paid seat on either, so we cannot report how inspectable that reasoning is in practice. What both let you do for certain is check the sources.

Which should a resident choose?

If you are in the US or Canada, OpenEvidence costs nothing and is worth having regardless. Whether you also need UpToDate usually depends on whether your programme provides it, whether you need its particular CME acceptance, and whether you want graded recommendations behind the decisions you document.

References

1. OpenEvidence. About. https://www.openevidence.com/about (read October 2026).

2. OpenEvidence. Homepage, NEJM partnership statement. https://www.openevidence.com/ (read October 2026).

3. EvidenceMD. Clinical AI Tools Pricing and Access 2026. https://evidencemd.ai/blogs/clinical-ai-tools-pricing-access (figures given as of July 2026; read October 2026).

4. Ali R, Abdulrazeq HF, Patil A, et al. AtlasGPT: a language model grounded in neurosurgery with domain-specific data and document retrieval. J Neurosurg. 2025;143:560-567. doi:10.3171/2024.12.JNS241607

5. Wolters Kluwer. UpToDate clinical solutions. https://www.wolterskluwer.com/en/solutions/uptodate (read October 2026). Editorial network size, clinician reach, EHR and Epic availability, CME acceptance, outcomes research.

6. OpenEvidence. Announcements, 2026. https://www.openevidence.com/announcements (re-read 3 November 2026). CE and MOC education platform (28 July 2026); free access for Canadian physicians (11 September 2026); Springer Nature agreement (5 August 2026); Sage partnership (29 September 2026); OpenEvidence Model Family (3 September 2026); UTMB workflow integration (22 September 2026); Northwestern Medicine EHR integration (12 October 2026); Johns Hopkins Medicine (13 October 2026); Behind the Knife (14 October 2026); Memorial Sloan Kettering (22 October 2026); ASAM (28 October 2026); NYU Langone Health Epic integration (29 October 2026); plus Penn Medicine, Boston Children's Hospital and AdventHealth collaborations. As of this reading the announcements page carries no UK or EU availability announcement and none describing a stepwise reasoning trace.

7. Google Search opportunity for AtlasGPT, September 2026 analyst review (internal; UK and EU market withdrawal, category pricing).

8. Wolters Kluwer. UpToDate Expert AI. https://www.wolterskluwer.com/en/solutions/uptodate/uptodate-expert-ai (read November 2026).

Last reviewed: November 2026.